90Y-besilesomab (TLX66) / Great Ormond Street Hospital for Children, Telix - LARVOL DELTA

Uncertainty analysis of single-time-point organ dosimetry compared with the multi-time-point method in radioimmunotherapy. (PubMed, EJNMMI Phys) - "The absorbed dose uncertainty in STP was significantly higher compared to the MTP. Incorporating the uncertainty analysis for STP dosimetry parameters in routine clinical practice is strongly recommended. The accuracy in the acquisition time, population-based half-life and fitting function for time activity curve is vital for minimising uncertainty in STP dosimetry, which is less time-consuming and easier to implement in clinical practice than MTP."

Journal • Hematological Disorders • Hematological Malignancies • Oncology

ANTIBODY TARGETED RADIOTHERAPY CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION: LONG-TERM FOLLOW-UP OF 40 PATIENTS WHO RECEIVED YTTRIUM-90 ANTI-CD66 IN A PHASE I/II TRIAL (EBMT 2026) - P1/2 | "On D -10 patients were admitted to start standard conditioning (fludarabine 30mg/m2 D-7 to D-3, CAMPATH IH 10mg D -10 to D-8 (sibling) or D -6 (unrelated donor), melphalan 140mg/m2 D - 2)...Of the 42 patients that received 111In-besilesomab, two had excessive hepatic uptake, excluded from receiving 90Y-besilesomab and received a standard transplant... The addition of an 90Y-anti-CD66 delivered up to 40Gy of radiation to the BM with no additional early or late toxicities while achieving sustained responses in patients with high risk diseases."

Clinical • P1/2 data • Acute Graft versus Host Disease • Alzheimer's Disease • Breast Cancer • Chronic Graft versus Host Disease • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Mood Disorders • Multiple Myeloma • Solid Tumor • Transplantation

Telix Featured in 13 Abstracts at the Annual Congress of the European Association of Nuclear Medicine (EANM) (PRNewswire) - "Telix's extensive theranostic pipeline will be showcased in presentations covering...TLX101 (131I-iodofalan or 131I-IPA) glioblastoma therapy; TLX66 (90Y-besilesomab) bone marrow conditioning therapy; TLX252 (225Ac-girentuximab) carbonic anhydrase IX (CAIX)-targeted alpha therapy..."

Clinical data • Glioma

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2024 ➔ Sep 2025 | Trial primary completion date: Oct 2023 ➔ Sep 2025

Enrollment open • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Trial primary completion date: Jun 2023 ➔ Oct 2023

Trial primary completion date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation

RITII: 90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia (clinicaltrials.gov) - P2 | N=25 | Not yet recruiting | Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Initiation date: Jan 2022 ➔ Apr 2022

Trial initiation date • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Oncology • Transplantation